Infection

Respiratory syncytial virus is an age-old winter foe that could affect many of your patients this year. Take a minute and scan these facts for a refresher.

Your daily dose of clinical news you may have missed.

One in 7 parents have not discussed vaccines with their child's primary clinician during the 2-year pandemic period, according to a CS Mott Children's Hospital poll.

Overall flu activity is at a 10-year high, according to the CDC's most recent influenza surveillance report, while US hospitals are already overwhelmed.

Early oseltamivir use reduced the length of hospitalization and risk for hospital readmission in children hospitalized with influenza, according to new research.

Confidence in vaccines is lower post-pandemic across all demographic groups and is not limited to traditional "anti-vaxxers," say authors of a new study.

I have admitted infants to the hospital every winter for 40 years, yet I still don't have good answers for anxious parents watching their child struggling to breathe.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.

Your daily dose of clinical news from Patient Care Online.

The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.

Elizabeth Sapey, PhD, discusses how the updated treatment recommendations from the World Health Organization may impact future use of remdesivir.

Elizabeth Sapey, PhD, discusses findings from the SOLIDARITY study and similar research on the efficacy of remdesivir for treatment of severe disease.

Elizabeth Sapey, PhD, discusses the updated recommendations and the research that prompted the decision.

This influenza antiviral brush-up slide show reminds you of key features of the 4 FDA-recommended medications, at-a-glance.

WHO: Evidence is lacking for clinical effectiveness of Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.

Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.

The performance of 3 commercially available COVID-19 home-testing kits worsened during the emergence of the omicron variant, according to a new cross-sectional study.

Get answers to 7 questions you may have regarding bivalent booster dose vaccination for patients from the US Centers for Disease Control and Prevention.

Steer clear of antibiotic Rxs whenever possible, says Anne Meneghetti, MD, to help the US get back to pre-COVID levels of antimicrobial stewardship.

Preventing viral infections with vaccination can keep the most vulnerable out of the hospital, reducing the risk of bacterial superinfections.

Only 9% of inpatients with COVID-19 had a bacterial superinfection that could be treated with antibiotics which curbed use of broad-spectrum antimicrobials.

Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.

Widespread antibiotic prescribing in the first year of the pandemic set back US progress on the fight against antimicrobial resistance, says Anne Meneghetti, MD.

A new real-world study found that two-thirds of patients with COVID-19 were still infectious 5 days and one-fourth at 7 days after symptom onset.

The FDA now recommends serial testing following a negative result on any at-home COVID-19 antigen test to reduce the risk of a false negative result.

After exposure to COVID-19, asymptomatic individuals in low-risk settings no longer need to quarantine, says the CDC; masking is still recommended.

Lyme disease vaccine being tested in phase 3 trial, Lyme disease diagnoses up 357%, and 3 more updates on tick-borne diseases.

A smaller dose given by intradermal injection will expand the total US supply by a factor of 5, FDA says.

Monkeypox will now be treated as a public health emergency in the US where the outbreak has become the largest in the world, according to authorities.